Colocación para recaudar US$4.2 millones
29 de febrero de 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").
MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.
Hemogenyx productos farmacéuticos plc
("Hemogenyx Pharmaceuticals" o la "Compañía")
Placing to Raise US $ 4.2 millones
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully raised US$4.2 million (£3.325 million) before expenses through the allotment and issue of 166,250,000 new ordinary shares at 2 pence per share (the "Placing", "Placing Shares").
The net proceeds from the Placing will be used to facilitate the development of the Company's Chimeric Antigen Receptor T-cells ("HEMO-CAR-T") for the treatment of acute myeloid leukaemia ("AML"). As announced on 9 February 2024, the Company was informed by the U.S. Federal Food and Drug Administration ("FDA") that it had lifted the clinical hold on the Investigational New Drug ("IND") application for HEMO-CAR-T for the treatment of AML. The funds have been raised to allow the Company to progress HEMO-CAR-T to phase 1 clinical trials.
An application is being made to the London Stock Exchange Main Market and admission of the Placing Shares to trading is expected on or around 6 March 2024 ("Admission"). The Placing Shares will rank al mismo ritmo con las acciones ordinarias existentes en la Compañía.
El Dr. Vladislav Sandler, director ejecutivo y cofundador de Hemogenyx Pharmaceuticals, comentó:
"We are extremely pleased to have raised these funds to allow us to progress our lead asset, HEMO-CAR-T, to clinical trials. This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T. I would like to thank new and existing shareholders for their support and for contributing to this sizeable fundraise in difficult market conditions. The recent lifting of the clinical hold by the FDA on our HEMO-CAR-T programme followed a great effort from everyone at Hemogenyx Pharmaceuticals for which I am very grateful."
Total de derechos de voto
A los efectos de las Normas de transparencia y orientación de divulgación, tras la admisión, el capital social emitido ampliado de la Sociedad comprenderá 1,341,815,988 acciones ordinarias. La Sociedad no mantiene acciones en tesorería. La cifra anterior puede ser utilizada por los accionistas como denominador para los cálculos mediante los cuales determinarán si están obligados a notificar su interés o un cambio en su interés en la Compañía, según las Normas de Transparencia y Guía de Divulgación.
For the purposes of UK MAR, the person responsible for arranging for the release of this Announcement on behalf of the Company is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Consultas:
Hemogenyx productos farmacéuticos plc | https://hemogenyx.com |
Dr. Vladislav Sandler, director ejecutivo y cofundador | |
Peter Redmond, director | |
SP Ángel Finanzas Corporativas LLP | Tel.: +44 (0) 20 3470 0470 |
Matthew Johnson, Vadim Alexandre y Adam Cowl | |
Peterhouse Capital Limited | Tel.: +44 (0) 20 7469 0930 |
Lucy Williams, Duncan Vasey y Charles Goodfellow |
Acerca de Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in Londres, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in Nueva York at its state-of-the-art research facility.
La Compañía es un grupo biofarmacéutico en etapa preclínica que desarrolla nuevos medicamentos y tratamientos para tratar enfermedades sanguíneas y autoinmunes y para llevar el poder curativo del trasplante de médula ósea a un mayor número de pacientes que padecen enfermedades incurables que amenazan la vida. Hemogenyx Pharmaceuticals está desarrollando varios productos candidatos distintos y complementarios, así como tecnologías de plataforma que utiliza como motores para el desarrollo de nuevos productos.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.